Medical Therapy of Acromegaly by Plöckinger, U.
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2012, Article ID 268957, 22 pages
doi:10.1155/2012/268957
Review Article
Medical Therapy of Acromegaly
U. Pl¨ ockinger
Interdisziplin¨ ares Stoﬀwechsel-Centrum, Charit´ e-Universit¨ atsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany
Correspondence should be addressed to U. Pl¨ ockinger, ursula.ploeckinger@charite.de
Received 30 October 2011; Revised 20 December 2011; Accepted 9 January 2012
A c a d e m i cE d i t o r :A .L .B a r k a n
Copyright © 2012 U. Pl¨ ockinger.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment,
postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated. Therapeutic
eﬃcacy of the diﬀerent available drugs—somatostatin receptor ligands (SRLs), dopamine agonists, and the GH antagonist
Pegvisomant—is discussed, as are the indications for and eﬃcacy of their respective combinations. Information on their
mechanism of action, and some pharmakokinetic data are included. Special emphasis is given to the diﬃculties to deﬁne remission
criteria of acromegaly due to technical assay problems. An algorithm for medical therapy in acromegaly is provided.
1.Introduction
Surgical therapy of acromegaly aims for elimination of the
tumour and normalisation of both, growth hormone (GH)
secretion and Insulin-like growth factor-1 (IGF-1) concen-
tration. Using conventional criteria for complete remission
(GH below 1.0µg/L during oral 75-g glucose load (OGTT)
and normal age- and sex-adjusted IGF-1 concentration) this
will be achieved in about 60% of the patients. However,
for patients with a macroadenoma (tumour diameter >
1cm) and/or large parasellar extension, the rate of complete
remission drops to 50% or less, even in experienced neu-
rosurgical centres [1–6]. Freda et al. suggested very strict
criteria for remission using a sensitive immunoradiometric
assay (GH below 0.14µg/L during OGTT and normal IGF-
1 concentration) [7]. However, for this criterion insuﬃcient
data are available to date. Of course, stricter criteria will
result in fewer complete remissions.
Medical therapy is indicated in those acromegalic
patients, who failed to achieve remission after surgery or in
the rare patient with contraindication for surgical therapy.
In addition, it is used in patients following radiotherapy in
order to bridge the interval until complete remission.
In the following a short overview on the indications for
medical therapy in acromegaly will be given. The diﬀerent
available forms of medical therapy will be treated in detail.
Preoperative medical somatostatin analogue treatment will
also be discussed. Finally, an algorithm for the medical
treatment of acromegaly will be proposed.
2. Indication for Medical Therapy
A high GH- and IGF-1 concentration persisting after incom-
pletesurgeryorprevailingintheﬁrstyearsafterirradiationis
a clear indication for medical therapy. In contrast, in patients
who just fail to reach the commonly accepted remission
criteria, or even fulﬁl the biochemical criteria but still
report discrete signs and symptoms of active acromegaly, the
decision to initiate lifelong medical therapy may be diﬃcult.
Thus it is important to shortly review the problems of
diagnosing persistent acromegaly in patients with a relatively
low GH concentration after pituitary surgery and relating
them to the commonly accepted remission criteria.
2.1. Remission Criteria. Cure of acromegaly as “restitutio
ad integrum” is not possible, due to the irreversible bone
changes. Thus, complete removal of the tumour, normal-
isation of the GH secretion and the IGF-1 concentration,
as well as preservation of pituitary function, are generally
aimed at. Criteria have been extensively discussed at diﬀerent
consensus conferences. The following criteria for complete
remission are adopted by most centres [8]:2 International Journal of Endocrinology
(i) a GH nadir below 1µg/L during an 75g oral glucose
load, GH determination at 30 minute intervals for at
least 120 minutes [8–16],
(ii) a normal age- and sex-adjusted IGF-1 concentration,
(iii) no visible tumour tissue on MRI.
However, highly sensitive assays demonstrated active acro-
megaly with a GH nadir during OGTT well below 1µg/L.
Freda et al. reported that ﬁve of ﬁfteen newly diagnosed
acromegalic patients reached a GH nadir during OGTT
below 1µg/L, even as low as 0.42µg/L. The IGF-1 concen-
tration was elevated in all patients, but signs and symptoms
of acromegaly were subtle in three patients. Postoperatively
acromegaly has been histologically conﬁrmed in all these
patients[17].Thesedatademonstratethepossibilityofactive
acromegaly even with very low GH concentrations. Thus
strictercriteria,usingasensitivemonoclonalassay,havebeen
proposed. These suggested criteria for remission refer to a
GH nadir below 0.4µg/L [1, 8, 17–20]o re v e n0 . 1 4µg/L [7].
2.2. Evaluation of Remission Criteria. Whether failure to
achievethesecriteriaforcompleteremissionofacromegalyis
identical totheindication formedicaltherapy isstill amatter
of debate. Most centres combine
(i) the results of biochemical investigations
(ii) the clinical outcome of surgery, that is, does
the patient still present signs and symptoms of
acromegaly,
(iii) theevaluationofthepatient’squalityoflife,asrecent-
ly has been suggested,
(iv) epidemiological data, that is, the impact of an elevat-
ed GH and/or IGF-1 concentration on survival.
Thus a failure to achieve complete remission after surgery is
by itself not necessarily an indication for medical therapy.
Moreover, the results for the nadir GH concentration
during an OGGT and the IGF-1 concentration may be diver-
gent or both tests may slightly fail to reach the predeﬁned
criteria. In such a case observation and reevaluation after, for
e x a m p l e ,6o r1 2m o n t h si sj u s t i ﬁ e d .
It has been proposed that patients with a mean GH
concentration <2.5µg/L in a 5-point day proﬁle need not
be treated medically, since they have a life expectancy
comparable to the normal population [21–23]. However,
in a recent consensus discussion, this criterion failed to be
seen as reliable and suﬃciently evidenced based. The GH
concentration determined by new and more sensitive assays
is generally lower compared to the earlier used polyclonal as-
says. Thus using a random or mean GH concentration as the
criterionfordiseasecontrol,aGHconcentration<1µg/Lwas
suggested at an endocrine tumour summit [24].
The signs and symptoms of acromegaly are diﬃcult to
judge, when GH is low, although persistently autonomous.
Reduced exercise capacity, lethargy, or sweating may be non-
speciﬁc. Follow-up and long-term observation of the quality
oflife(QoL)usinganacromegalyadjustedquestionnaire[25,
26] can be helpful in assessing the activity of autonomous
GH secretion. Using the AcroQoL questionnaire Paisley et al.
were able to show a negative correlation between well-
being and the IGF-1 concentration, that is, higher QoL
with IGF-1 concentration approaching normal values [27].
Bonapart et al. suggested that quality of life measurements
may be able to uncover those patients who despite a
normalisation of biochemical indicators still have active
disease which possibly warrants further treatment [28]. Thus
quality of life evaluation may oﬀer additional clues with
respect to treatment indications. Yet the signiﬁcance of
QoL questionnaire in the evaluation of acromegaly and/or
treatment eﬀects is still a matter of debate, as either negative,
neutral,orpositiveeﬀectsofbiochemicalimprovementshave
been demonstrated [29–31], or a positive impact has only
been obvious for subscales on the QoL evaluation [32]. The
lack of correlation between QoL and biochemical markers of
the disease does not come as a surprise, as duration of the
disease, extent of physical disﬁgurement, and comorbidities
may have additional and individual impacts on the quality
of life with acromegaly. Thus further and more detailed
investigations will be needed, adjusting the results of QoL
questionnaires to the aforementioned aspects, before QoL
questionnaires will gain a major impact on the process of
therapeutic decision making.
2.3. Technical Considerations. To establish the eﬀect of
surgical therapy several considerations have to be taken in
account:
2.3.1. Timing of the Postoperative Evaluation. Postoperative
evaluation should be performed 3 to 6 months after surgery
[8, 15, 33]. Earlier investigation, that is, an oral glucose load
one week after surgery, has been claimed to be as reliable
[8, 33]. However the IGF-1 concentration can take months
to normalise and up to 30% of patients, especially those with
discordant biochemical results, change their status within
one yearoffollow-up.Henceevaluationaftera3to6months
interval is supposed to be the most reliable [15, 33–36].
The slow decline of the IGF-1 concentration is probably
related to the high sensitivity of the liver after surgery, due
to the now lower GH concentration. This may result in a
delayed reduction of the IGF-binding-protein concentration
and thus persistently increased IGF-1 concentration. The
IGF-1 concentration may be elevated, despite an already
normal GH suppression during OGTT, leading to divergent
results. This can be observed in up to 30% of postoperative
patients [16, 19]. The discrepancy can normalise over time,
but it can also be related to minimal persistent autonomous
GHsecretionandthusindicatethepossibilityofrelapse[15].
2.3.2. Discrepancy between the GH Nadir during OGTT and
the IGF-1 Concentration. The observed discrepancy between
the GH nadir during an oral glucose load and the IGF-1
concentration is a major problem for the interpretation of
biochemical indices of disease activity. The problem may be
due to the diﬃculties in deﬁning remission criteria for both,
the GH-suppression by an oral glucose load and the normal
IGF-1 concentration [8, 15–18, 20, 34, 35, 37–40].International Journal of Endocrinology 3
This may be due to (i) altered dynamics of the GH
secretion after surgery, (ii) inadequate GH nadir values (not
adjusted to age, sex, and BMI), or (iii) to the inﬂuence of
concomitant medication (i.e., SRLs, see below). In patients
with radiotherapy the relation of GH to IGF-1 is disturbed
and cannot be relied upon [41].
A divergence between the concentration of IGF-1 and
the GH nadir during OGTT has been observed in both
directions,thatis,anincreasedIGF-1andanormalGHnadir
or a normal IGF-1 and insuﬃcient suppression of the GH
concentration [15, 42–44]. Both groups may demonstrate
a change of their test results during long-term follow-up,
indicating the diﬃculties with the deﬁnition of “complete
remission” [45]. These uncertainties render the role of IGF-
1 or the GH nadir during OGTT as the sole parameter
for the estimation of prognosis (recurrence, morbidity, and
mortality) of acromegaly problematic [10, 46, 47].
2.3.3. Growth Hormone Assay. The various available assays
for the determination of GH use diﬀerent antibodies with
distinct aﬃnity to the GH molecule. These antibodies may
recognise not only separate epitopes but even diﬀerent
GH isoforms. Most will recognize the 22kD form of the
GH molecule. Unfortunately the spectrum of isoforms
recognised is rarely indicated. Furthermore the reference
preparation used for the assay may diﬀer between assays.
Thus GH determination with diﬀerent assays leads to diver-
gent results. The diﬀerence between two assays for one GH
sample can exceed 100% [48]. As the results of diﬀerent
assays are not comparable, each assay system needs its own
reference value. This is important, since assay systems may
change over time causing problems for the interpretation
of results during long-term follow-up. Today most assays
are sandwich chemiluminescence assays using a monoclonal
antibody. These assays are very sensitive with a lower limit of
detection of 0.002µg/L to 0.2µg/L.
Preanalytic handling is straight forward as GH, in a
serum sample, remains stable for at least 24 hours [49]. In
addition physiological variables such as age, sex, body mass
index (BMI kg/m2), and the concentration of GH-binding
protein (GHPB) may inﬂuence the GH concentration and
the response to an oral glucose load. Generally GH con-
centrations are lower in older, obese, or male compared to
younger, lean, or female subjects and patients [13]. So far,
no data exist to adjust the nadir GH concentration during
OGTT or the mean GH concentration during a GH proﬁle
for age, sex, and obesity [48]. This again highlights the
diﬃculties in deciding on medical therapy based on the
postoperative biochemical indicators in acromegaly [50].
2.3.4. Insulin-Like Growth Factor-1. A normal IGF-1 con-
centration is not generally accepted as the only criterion
for complete remission. In retrospective analyses of long-
term outcome in acromegaly a normal IGF-1 concentration
correlated positively with a normal survival of the patients
[14, 23, 51, 52]. However there are valid arguments indicat-
ing that IGF-1 as the only determinant of remission may be
insuﬃcient. Postoperative normalisation of IGF-1 can take
some time [53] (see above). False low values may be due to
surgical stress or fasting, as both physiologically reduce the
IGF-1 concentration. In addition numerous problems with
the IGF-1 assay make IGF-1 an even less reliable parameter
than the glucose-suppressed GH nadir. The possible pitfalls
of the IGF-1 determination are either due to technical issues
related to the assay system or to the reference preparation. In
addition physiological variations of the IGF-1 concentration
have to be taken into account.
2.3.5. IGF-1 Assay
(i) Poor assay standardisation is one of the basic
problems. The only available standard preparation
(87/518) is impure, containing only 40% of IGF-1.
(ii) IGF-binding proteins interfere with the antibody
used to measure the IGF-1 plasma concentration. To
reduce this interference several methods with varying
eﬃcacy are used. The “gold standard” is the addition
of IGF-2. IGF-2 has a higher binding aﬃnity for IGF-
binding proteins than IGF-1. Adding IGF-2 during
an ethanol extraction procedure reduces this kind of
interference.
(iii) The variability of the IGF-1 determination can be
substantial. Two samples, measured at baseline and
after two weeks, showed an overall good correlation
(r = 0.922, P<0.0001). However the reported
diﬀerences ranged between −36.25% and +38.24%
[54]. Intraindividual variability ranged from 3% to
36% [55].
(iv) Recently it was demonstrated, that even two high
quality assays, using the same international standard,
were not comparable [42].
2.3.6. Reference Populations and Physiological Variations
(i) The IGF-1 concentration is age dependent. Hence
age-adjusted reference values have to be provided by
each manufacturer. However most available assays
provide insuﬃcient data for reliable interpretation
of the IGF-1 results [56]. Normative data have been
published [57]. Unfortunately shortly thereafter, the
assay system used (Nichols IGF-1 assay) was no
longer available.
(ii) In patients with poorly controlled diabetes mellitus
or malnutrition IGFBP-1 and IGFBP-2 concentra-
tions increase, rendering the determination of IGF-1
diﬃcult [40].
(iii) A number of clinical conditions will inﬂuence the
IGF-1 concentration such as BMI (especially a BMI
below 22 or above 37), ethnicity, chronic renal or
hepatic failure, chronic undernutrition, and medica-
tion such as oral contraceptives [55, 58, 59].
The relative unreliability of the IGF-1 determination became
even more a problem after the introduction of a GH
antagonist, since the determination of the GH concentration4 International Journal of Endocrinology
is not meaningful during therapy [48, 60]. Details of medical
therapy with a GH-antagonist will be discussed below.
Thus, while the decision for treatment with a GH receptor
antagonist may still rely on the nonsuppressibility of GH
duringOGTT,thefollow-upduringtherapyanddoseadjust-
ment have to be based on a methodology demonstrated to
lack suﬃcient sensitivity for the diagnosis of remission in
acromegaly.
2.4. Conclusions. Indications for medical therapy are
(i) failure to suﬃciently reduce GH secretion by surgery,
(ii) bridgingthetimelaguntilcompleteremissionwillbe
achieved after irradiation,
(iii) the rare patient with contraindication to surgery.
Recommended criteria for initiation of medical therapy
are
(i) an insuﬃciently suppressed GH nadir (>1µg/L)
during an oral glucose load,
(ii) an increased age-adjusted IGF-1 concentration.
In patients with borderline results of the above discussed
criteria decisions on the following considerations may sup-
port the decision for medical therapy,
(i) a mean GH concentration above 2.0µg/L–2.5µg/L
during a ﬁve-point GH-proﬁle,
(ii) the clinical activity of acromegaly,
(iii) the subjective activity of acromegaly investigated by
the AcroQoL questionnaire.
Due to the diﬃculties in normative values for complete
remission, the clinician is well advised to add clinical judge-
ment and the severity of signs and symptoms of acromegaly
into the decision algorithm for medical therapy [61].
3. Options for Medical Therapy
Medical therapy aims to achieve complete remission. Thus
criteria already discussed will guide therapeutic decisions.
Any deviation will be discussed when appropriate. The
availabledrugsarelong-actingsomatostatinreceptorligands,
dopamine agonists with low overall eﬃcacy and the highly
eﬀective GH antagonist Pegvisomant.
3.1. Somatostatin Receptor Ligands (SRL)
Mechanism of Action. GH secretion is physiologically reg-
ulated by the interaction of stimulating and inhibiting
hypothalamicpeptides,growthhormonereleasinghormone,
and somatostatin, respectively. Somatostatin inhibits GH
secretion from the pituitary somatotroph cells by bind-
ing to somatostatin receptors (sst). So far ﬁve diﬀerent
human somatostatin receptor subtypes, sst1, sst2A, sst3-
5, are known. Binding of somatostatin to sst results
in a G-protein-coupled activation of adenylate-cyclase.
The intracellular signal transduction is dependent on the sst-
subtypeandthetissueinvolvedandmayincludereducedCa-
inﬂux, activation of phosphotyrosine-phosphatase, signal
transduction pathways via STAT-5 or MAP-kinase, and
activation of phospholipase A and C. Tentatively some
speciﬁc roles may be related to each receptor: control of GH
release via sst2 and sst5, modulation of insulin and glucagon
secretionviasst5,inductionofapoptosisviasst3andpossibly
sst2, inhibition of the cell cycle via sst1 and sst3. Sst1 may
play a role in angiogenesis, while the function of sst4 is
still unknown. In comparison with normal pituitary tissue,
somatotroph adenomas are characterized by a higher density
of sst2 and sst5. The expression of sst in adenoma tissue
is inhomogeneous and tumour speciﬁc. This may partly
explainthevariableresponsesofindividualadenomastoSRL
therapy [62].
Validating the presence of sst2 and sst5 on adenoma
tissue has been suggested to allow the prediction of clinical
eﬃcacy of SRL. However immunohistochemical application
for in vitro diagnostic has been hampered due to the lack of
monoclonal and speciﬁc polyclonal anti-sst2 and sst5 anti-
bodies. The use of two novel rabbit monoclonal anti-sst2A
and anti-sst5 antibodies allowed for a several times more
eﬀective immunhistochemical staining for both, sst2A and
sst5, respectively. Sst5 was seen in all, sst2 in 83% to 85% of
the somatotropinomas. However, interindividual variability
inthepercentageofpositivecellsandtheintensityofstaining
waspronounced[63–65].Applyingthisspeciﬁcandsensitive
sst2A antibody we demonstrated that selective loss of sst2A
correlatedtoOctreotideresistanceinsomatotrophadenomas
[66]. Thus, using these highly sensitive tools may allow the
prediction of an adenoma’s response to SRL and even the
selection of receptor-speciﬁc SRL.
On most tumours more than one sst subtype can
be found. It has been shown that sst interact with each
other or with other G-protein coupled receptors forming
homo- or heterodimers, further increasing the complexity of
somatostatin receptor activation. Receptor dimerisation may
modify the receptor-ligand internalisation process, intracel-
lular transduction signalling, and receptor recycling. Thus
sst2A-sst3heterodimerisationresultedinanewreceptorwith
enhanced sst2A-like and diminished sst3-like activity [67].
Grant and Kumar demonstrated that sst2 and sst5 form
heterodimers upon subtype-speciﬁc sst2 ligand activation
[68]. This process leads to alterations in cell growth and may
be responsible for the lack of tolerance seen in SRL treatment
of pituitary tumours. Yet most of the speciﬁc mechanisms
inducing receptor dimerisation, as well as the molecular
consequences of this process, are still not clear. Further
investigations are necessary to predict the eﬀects of these
many interactions on the decline of the GH concentration
and inhibition of tumour growth.
Antiangiogenesis has been discussed as an additional
mechanismofSRL.Somatostatininhibitsangiogenesiseither
directly or via growth factors, that is, vascular endothelial
growthfactor(VEGF),basicﬁbroblastgrowthfactor(bFGF),
and IGF-1 or through its immunomodulatory eﬀects [69].
Recentlyithasbeenpostulatedthattheantiangiogeniceﬀects
of SRL may aﬀect tumour growth of pituitary adenomas.International Journal of Endocrinology 5
The extent of neovascularisation, as well as the expression of
VEGF, correlates positively with the degree of invasiveness in
some pituitary adenomas [69]. On the other hand pituitary
tumours have been shown to be less vascular than the
normal pituitary tissue [70]. This may explain the slow
growth velocity of most pituitary adenomas. Interestingly
in somatotropinomas microvessel density was negatively
correlated with the patients’ age, possibly explaining the
clinical observation of more aggressive somatotroph adeno-
mas in young compared to older adults [71–73]. Reduced
angiogenesis in somatotroph adenomas may hamper the
postulated antiangiogenic eﬀect of SRLs on tumour growth.
Using the chicken chorioallantoic membrane model Barrie
et al. demonstrated the most pronounced antiangiogenetic
eﬀect by those SRL which preferentially activate sst2, like
Octreotide or RC-160 [74]. Thus the presence of sst2, which
is the dominant sst in most somatotroph adenomas, may be
decisive for an antiangiogenetic eﬀect by these drugs. For
a detailed discussion of antiangiogenetic eﬀects of SRL see
Dasgupta [69].
Somatostatin Receptor Ligands Octreotide and Lanreotide.
The clinical available somatostatin analogues Octreotide
and Lanreotide demonstrate a high aﬃnity for sst2 and a
moderate aﬃnity for sst5. The inhibition of GH secretion
is mostly conveyed via sst2. However, as already discussed,
receptor interactions modulated by subtype speciﬁc SRL
may profoundly inﬂuence the mechanisms of action of SRL.
In addition to the inhibition of GH secretion the native
somatostatin, as well as the SRL, also reduce the secretion of
insulin, glucagon, cholecystokinin and gastrin. For details on
dosing and the duration of action see Table 1.
3.1.1. Subcutaneous SRL Treatment. Octreotide and Lan-
reotidearecyclicpeptideswithasigniﬁcantlyprolongedhalf-
life compared to somatostatin (2 hours versus 2 minutes).
Only Octreotide is available for subcutaneous therapy. In
monkeysOctreotideinhibitstheGHsecretion45timesmore
than somatostatin [75]. Initially Octreotide was available
for thrice daily subcutaneous injections. The doses used
ranged from (50)–100µg up to 500µg three times a day. This
regimen resulted in ﬂuctuating drug concentrations, with an
increase in GH usually observable six hours after the injec-
tion [76]. Octreotide (median 300µg/d) treatment of 189
acromegalic patients with a wide range of pretreatment GH
concentrations and various forms of pretreatment resulted
in a GH and IGF-1 concentration <5µg/L in 83/189 (45%)
and <2mU/L in 46/99 (46%) of the patients, respectively
[77]. Comparable results were published by Ezzat et al. in a
similar population of 152 acromegalic patients treated with
two diﬀerent dose regimens (300µg/d or 750µg/d). A GH
concentration <5µg/L was achieved in 53% and 49%, the
IGF-1 concentration normalized in 68% and 55% of the
patients,respectively[78].Thenowmorestringentremission
criteria,aswellaschangesintheIGF-1determination,donot
allow for a strict comparison with more recent results. Today
subcutaneous therapy has been superseded by long-acting
preparations. However, subcutaneous SRL treatment may
still be indicated (i) in patients who need only very low doses
of SRL to achieve remission criteria or (ii) in the rare patient
with substantial hair loss during treatment with long-acting
formulations, as this side eﬀect may be less pronounced with
the formulation for subcutaneous injections.
3.1.2. Slow Release Formulations of SRL. The introduction
of slow release formulations, Octreotide long-acting repeat-
able (LAR), Lanreotide slow release (SR), and Lanreotide
Autogel makes possible an intramuscular or deep subcuta-
neous injection every 2–6 weeks (Table 1) .T h em o r ec o n -
stant plasma concentration of the long-acting formulation
resulted in a slightly higher eﬃcacy of Octreotide LAR versus
subcutaneous therapy in 152 patients treated consecutively
with both formulations [79]. Slow release formulations
are more convenient for the patients and thus compliance
is increased. Diﬃculties with injecting Octreotide LAR
or Lanreotide Autogel can be reduced by delivering the
injections with the help of speciﬁcally trained personnel.
Therapeutic Eﬃcacy of SRL. SRL inhibit both, the physiolog-
icalandtheautonomousGHsecretion.Notachyphylaxiahas
been observed during long-term therapy. This is in contrast
to the declining eﬃcacy in neuroendocrine gastrointestinal
tumours treated with SRL. Treatment eﬃcacy with SRL is
assessed by using the basal or mean GH concentrations
(<2.5µg/L)and/ornormalisationoftheIGF-1concentration
as already discussed. The GH nadir during an oral glucose
load may not be helpful during SRL treatment for the assess-
ment of therapeutic eﬃcacy due to the high frequency of
discordantresults,thatis,anormalIGF-1—butinsuﬃciently
suppressed GH concentration during OGTT. This may be
due to (i) an SRL-induced direct suppression of the IGF-
1 generation of the hepatocyte or (ii) a disturbance of the
physiologic response of GH to oral glucose induced by SRL.
In this case the failure to suﬃciently suppress GH secretion
by an oral glucose load is a treatment induced artefact [16]
and this has to be kept in mind while interpreting published
results. Octreotide LAR—and slightly less often Lanreotide
SR—used as an adjunctive treatment after surgery, induces
complete remission, deﬁned by either a mean GH < 2.5µg/L
and/or a GH nadir < 1µg/L during OGTT, in 56% and 49%
ofthepatients,oranormalisationoftheIGF-1concentration
in 66% and 48%, respectively. During primary therapy,
remission criteria for GH or IGF-1 were achieved by both
SRL in 50% or 60%, respectively [80]. Therapeutic results
were negatively correlated to the basal GH concentration
[80].
While Lanreotide SR has been shown to be slightly
less eﬀective than Octreotide LAR, a comparable eﬃcacy
has been demonstrated for Octreotide LAR and Lanreotide
Autogelintwoclinicaltrials[81,82].Schopohletal.switched
37 patients on Octreotide LAR to Lanreotide Autogel.
Both regimens achieved comparable results concerning the
percentage of patients in remission as well as the mean GH
(mean of a 5-point GH proﬁle) or the IGF-1 concentration.
In 50% of the patients the injection interval could be6 International Journal of Endocrinology
Table 1: Dosage and duration of action of diﬀerent SRL.
Substance Application Dose range Duration of action
Octreotide Subcutaneous 150–300 (1500) µg/d ∼6–8 hours
Octreotide LAR Intramuscular 10–30mg/month ∼4w e e k s
Lanreotide SR Intramuscular 10–20mg/10–14 days ∼2w e e k s
Lanreotide Autogel Deep subcutaneous 60–120mg/4–6 weeks ∼4–6 weeks
prolonged with Lanreotide Autogel, an advantage much
appreciated by the patients [81].
In a further meta-analysis Freda conﬁrmed their earlier
results [80] and added follow-up information. The response
rate increased over time [46]. Colao et al. reported their 5-
years observational data in 45 de novo acromegalic patients.
A surprising 100% and 98% control for the fasting GH
(<2.5µg/L) and the IGF-1 concentration, respectively, was
achieved. Again there was no diﬀerence between Octreotide
LAR and Lanreotide Autogel [83]. The comparable eﬃ-
cacy of both, Octreotide LAR and Lanreotide Autogel has
been further conﬁrmed in a meta-analysis investigating the
potency of diﬀerent SRL formulations [84]. The clinical
eﬀects of SRL appear rapidly and often seem more pro-
nounced than suggested by the biochemical results. Excellent
eﬀects are reported concerning headache, hyperhidrosis, soft
tissue swelling, arthritic pain, and carpal-tunnel syndrome.
Objective positive eﬀects occur for the cardiovascular system
(reduction of left ventricular hypertrophy, improvement of
left ventricular ejection fraction) and hypertension [83, 85],
prostrate (volume reduction) [86, 87], sleep-apnoea [88–90]
and an improvement in renal structure and function [91].
SideEﬀects. SubcutaneousOctreotideinjectionscanresultin
reddening of the skin and burning sensations at the injection
site. This can be prevented by warming the drug to room
temperature before injection (storage is normally in the
refrigerator). With the depot preparation the injection is eas-
ilyperformed,ifinstructionsforpreparingtheintramuscular
injection are properly adhered to. Lanreotide Autogel can be
self-injected by the patients.
All SRL induce nonspeciﬁc abdominal discomfort with
nausea, ﬂatulence, and loose stools during the ﬁrst 3–5
days. These symptoms are mostly due to an inhibition
of the exocrine pancreas secretion. In rare cases problems
persist with steatorrhea and malabsorption. The addition of
pancreatic enzymes resolves these problems.
The eﬀect of SRL on glucose tolerance is not predictable.
GH reduces the insulin sensitivity. The reduction of the GH
concentration by SRL thus improves insulin sensitivity and
hence the drug-induced inhibition of insulin secretion can
be without negative eﬀects on glucose tolerance. However in
most patients SRL therapy slightly impairs glucose tolerance.
Yet the clinical relevance is not clear. During an OGTT the
ﬁrst phase of insulin-secretion is reduced and the subsequent
insulin increase is delayed.
However, the integrated insulin concentration is only
slightly reduced [92]. Depending on the individual situation
(obesity, metabolic syndrome, age) SRL can nevertheless
induce diabetes mellitus. Patients with pre-existing diabetes
mellitus may have an increased or reduced need of insulin
treatment, and thus a tight control of blood sugar is
mandatory in this group when SRL is initiated. Poor control
of acromegaly predicted a deterioration of glucose tolerance
during long-term treatment in patients on SRL therapy [76,
92–96].
SRL induce the inhibition of cholecystokinin secretion
andthesynthesisofamoreviciousandlithogenicbile,result-
ing in gallbladder sludge or gallstones in up to 30% to 60%
of the patients, respectively [97]. This complication occurs
lessoftenwiththedepotpreparations.Todissolvegallbladder
sludge, both chenodeoxycholic acid and ursodeoxycholic
acid are highly eﬃcient. Immediately after the conclusion of
subcutaneous Octreotide therapy a short-lived hyperactive
gallbladder contraction can be observed. This may give rise
to biliary complications in patients with gallbladder sludge
or gallstones. Probably due to the longer washout phase
of depot preparations no such complications have been
reported with the slow release formulations.
SRL reduce gastrin secretion. Together with a direct
inhibitory eﬀect at the parietal cell of the gastric mucosa,
gastric acid—and probably intrinsic factor secretion—is
reduced. Thus there is an increased risk of chronic gastritis
and, with long-term therapy, a decline of the vitamin B12
concentration [97, 98]. This may be compensated by a
monthly intramuscular injection of cyanocobalamin.
In rare cases an increase of liver function enzymes may
occur. Thus control of these parameters is recommended
every 6 months.
Diﬀuse alopecia is rare and occurs less often with the
subcutaneous than with the slow release preparation and is
reversible after discontinuation.
Practical Issues. Individually the result of SRL therapy is
not predictable. A test dose of Octreotide (50µg or 100µg)
injected subcutaneously followed by a GH-proﬁle can have
some prognostic value [99–101]. In contrast the positive and
negative predictive values of GH suppression <2µg/L for
long-term normalization of IGF 1 during Octreotide LAR
therapy were 56% and 75%, respectively, in an investigation
bydeHerderetal.Theauthorsconcludedthatthetestcannot
be recommended as a tool for clinical decision making on
further therapy [102]. Overall the predictive value is limited
as (i) the positive predictive value is higher for Octreotide
LAR than Lanreotide SR [101], (ii) about 20% of patients
withanegativetestresultmayreactwithaGHdeclineduring
long-term medication, and (iii) the results are dependent on
the criteria used to deﬁne remission.International Journal of Endocrinology 7
The eﬃcacy of the depot preparation should not be
evaluated before steady-state drug concentrations have been
achieved, that is, after 3 injections for Octreotide LAR.
Immunohistochemical determination of the sst2 may
oﬀer a better prognosis of the drug eﬀects. As has been
already mentioned, no tumour lacking sst2A immuno-
histochemical positivity demonstrated an eﬀect of SRL
therapy [66].
Somatostatin scintigraphy does not correlate with the ef-
fects of SRL on GH [103].
In most cases a three-month intervention with a long-
acting SRL will clarify the eﬀectiveness of SRL therapy.
With long-term therapy the SRL dose can be reduced in
most patients. The determination of the GH and IGF-1
concentration should be performed immediately before the
next injection, that is, at the nadir of the drug’s plasma
concentration.
3.1.3. Preoperative SRL Treatment. Transsphenoidal surgery
of a pituitary adenoma achieves complete remission in about
60%ofthepatients.Thepercentagemayevenbelower,when
newerandstrictercriteriaofremission(GHnadir <0.14µg/L
during OGTT) are taken into considerations. Surgical results
correlate with tumour volume, especially so with supra-
and parasellar adenomas, and with the preoperative GH
concentration [1, 3, 10, 37, 52, 104–107]. Presurgical SRL
therapyhasbeenseenasapossiblemeanstoimprovesurgical
outcome in patients with a macroadenoma.
Tumour Shrinkage. SRL reduce tumour volume in about
50%ofpreviouslyuntreatedacromegalicpatients.Theextent
oftumourshrinkageinthesepatientshasbeenreportedtobe
as high an 50%. However a critical meta-analysis by Melmed
et al. showed overall signiﬁcant tumour shrinkage—deﬁned
as at least 10% volume reduction—occurred only in up to
36.6% of therapy naive patients. The mean tumour volume
reduction was 19.4% for the whole cohort, irrespective of
whether individually signiﬁcant shrinkage occurred [108].
This paper included deﬁnitions of tumour shrinkage over a
wide range of volume reduction (from shrinkage of more
than 2mm, or 10% to 45%). There are some caveats
with respect to these data. Firstly percentage reduction is
of diﬀerent signiﬁcance whether calculated by the largest
diameter or by volume reduction. Secondly it has been
demonstrated that intra- and interindividual estimation of
tumour volume by MRI may vary up to 20%. Thus any
tumour volume reduction below 20% may be within the
variability of the imaging method [109].
MechanismofTumourShrinkage. Themechanismoftumour
shrinkage is still not fully understood. SRL are not cytotoxic.
Tumour shrinkage is probably in part due to an inhibition
of the GH synthesis and subsequent volume reduction of the
intracellular organelles involved in hormone production and
intracellular transport. However, no consistent morphologi-
cal changes have been observed [110–112].
Immunohistochemically SRL treatment induced a lower
expression of Ki-67 staining, an indicator of dividing cells,
compared to untreated somatotropinomas. The lower Ki-67
index indicates a suppressive eﬀect of SRL on cell cycling
[113]. Similar ﬁndings have been presented by Thapar
et al. demonstrating a decreased growth fraction and an
increased proportion of cells in G1 and M-phases. Thus the
antiproliferative eﬀects of SRL are probably related to an
inhibition of cell growth, that is, reduced cell cycling rather
than an increase in apoptosis [113, 114]. After discontinua-
tion of SRL the process is reversible and tumour volume may
increase within days [78, 115, 116].
Practical Issues. The duration of treatment necessary to
induce signiﬁcant tumour shrinkage is variable. In most
responding patients tumour shrinkage can be observed
within 3–6 months, while some may need SRL therapy up
to one year to achieve signiﬁcant volume reduction.
The analysis of factors predicting tumour response to
SRL treatment does not show clear-cut correlations. Bevan,
in a careful review, found contradictory reports with respect
to the positive correlation of pretreatment tumour volume
and response to SRL. Tumour shrinkage does occur in
both, macro- and microadenomas [117]. Similarly, the
GH or IGF-1 response to SRL as a prognostic factor for
successful tumour shrinkage has been controversial. While
some authors found that the decline of GH and/or IGF-
1 concentration predicted tumour shrinkage in therapy
naive patients, other could not demonstrate a correla-
tion between biochemical eﬃcacy and tumour shrinkage
[117].
Volume reduction is most eﬀective in preoperative,
that is, therapy-naive patients. Tumour volume reduction
is generally less in tumour remnants or after irradiation.
In those patients tumour shrinkage has been reported in
27%, while shrinkage occurred in up to 52% in therapy-
na¨ ıve patients [117]. Scarring and therapy-induced ﬁbrosis
may prevent signiﬁcant tumour shrinkage in pretreated
patients. SRL eﬀects on tumour volume are independent
of drug formulation. They have been observed with the
subcutaneous injections of Octreotide as well as with the
slow release preparations. In earlier publications increasing
doses of s.c. injections were positively correlated to tumour
shrinkage [78], while no such correlation was reported with
the slow release preparations [118, 119]. This may be due to
the more constant plasma concentrations of the drug with
slowreleaseformulationsandapossibleceilingeﬀect.Results
ofsomatostatin-receptor scintigraphy do not predict tumour
volume reduction [103].
Eﬀect of Preoperative SRL Treatment on Surgical Out-
come. Early publications suggested that presurgical therapy
improves surgical outcome [120, 121]. However results of
later reports were heterogeneous. An important improve-
ment of surgical results in pretreated patients was reported
by Colao et al. with a remission rate of 55% (N = 12)
versus 30% (N = 11) in treated versus untreated patients,
respectively[122].AhigherremissionratebypresurgicalSRL
treatment was observed in patients with enclosed adenomas,
but not in patients with invasive adenomas [123]. On the8 International Journal of Endocrinology
otherhandAbeandLuedeckesawanimprovementespecially
in invasive adenomas [124]. However, others could not
conﬁrmanyadvantageofpresurgicalSRLtherapy,neitheron
short- or long-term postoperative comparisons [125–127].
Data from prospective randomized trials showed either
(i) no statistical diﬀerence between patients pretreated or
operated on without pretreatment (remission rate 55% and
69%, resp.) [128], (ii) a small, nonsigniﬁcant improvement
(45% versus 23%, P = ns, pretreated versus primary
surgery) [129], or (iii) a remarkable improvement (49%
versus 18% P<0.001, pretreated versus primary surgery)
[130]. However, if only macroadenomas were analysed,
Carlsen et al. found a signiﬁcantly better surgical outcome
for those patients pretreated with SRL (50% versus 16%)
[129].
Thus it is still an open question whether presurgical
therapy with subsequent tumour shrinkage really improves
short- or long-term outcome of transsphenoidal surgery
in acromegaly. It is possible, however, that in centres with
relatively little surgical experience SRL pretreatment may
improve surgical outcome, while results of very experienced
centres cannot be further improved. Moreover, patients with
a microadenoma will probably not proﬁt from presurgical
SRL treatment, while those with large macroadenomas may
beneﬁt [24, 61].
In addition to complete remission of autonomous GH
secretion the preservation of pituitary function is an addi-
tional surgical goal. On this there is very little information.
Our own investigation showed no positive eﬀect of presurgi-
cal SRL treatment on the conservation of pituitary function
[126].
Furthermore it has been shown that perioperative risk
factors such as hypertension, poor cardiovascular-, pul-
monary function, and diabetes mellitus may be positively
inﬂuenced by preoperative SRL therapy. Reduction of soft
tissue swelling occurring early in the time course of med-
ical treatment may reduce diﬃculties of intubation. Thus
presurgical therapy may be indicated in high-risk patients
andshouldbediscussedwiththeanaesthetist[122,131,132].
3.1.4. Primary SRL Therapy. Primary medical therapy is
deﬁned as any medical therapy instead of surgery. Possible
indications for primary medical therapy are (i) patient’s
preference, (ii) comorbidities that pose an anaesthetical or
surgical risk, and (iii) possibly very old age [133]. In addition
primary therapy may be discussed in patients with with an
adenoma with large parasellar extension. In most of these
cases surgery will fail to cure the patient. While surgery
aims to remove all adenoma tissue, primary medical therapy
triestoachievebiochemicalremission,preventionoftumour
growth, and possibly tumour volume reduction.
Several prospective nonrandomized trials as well as one
retrospective analysis compared patients with primary and
secondary SRL treatment. No signiﬁcant diﬀerence of ther-
apeutic eﬃcacy was reported [119, 134, 135]. A publication
from Baldelli et al. reported an even better result for primary
therapy using Lanreotide SR [136]. Thus, in selected patients
primary SRL treatment may oﬀer an eﬀective alternative to
surgery. Importantly tumour growth during SRL therapy is
very rare (Table 3).
However, there are some caveats: (i) none of these studies
was randomized, (ii) in experienced hands the surgical risk is
low, even in very old patients [137], and ﬁnally (iii) lifelong
SRL treatment is very expensive.
3.1.5. New Developments. New developments aim to ﬁnd
SRL with improved ligand-binding characteristics, as
Pasireotide (Pasireotide), a multireceptor ligand or chimeric
ligands binding to both, sst and dopamine D2 receptors.
Somatostatin Multireceptor Ligands
Pasireotide (SOM 230). Pasireotide is an SRL with high
aﬃnity to sst-subtypes 1, 2, 3, and 5 [138, 139]. In
comparison to Octreotide, Pasireotide has a longer half-
life (2 hours versus 27 hours) [140]. This may be related
to the intracellular dynamic of the sst2- and sst5-receptor-
ligand complex. Both are internalised after ligand binding.
However, sst5 is rapidly and extensively recycled from
intracellular stores back into the cell membrane. Due to its
long half-life, Pasireotide can bind again to the recycled sst5.
Adenomas from patients resistant to the eﬀect of Octreotide
on GH secretion have been shown to express a high number
of sst5. Thus Pasireotide may be especially eﬀective in
these patients. The high aﬃnity of Pasireotide for sst1 and
sst3 may prove to be an advantage for the stabilisation of
t u m o u rg r o w t h .T h e s er e c e p t o r sa r ep r e f e r e n t i a l l yi n v o l v e d
in growth inhibition. Both inhibit the progression of the
cell cycle and induce apoptosis. A recently published study,
compared Octreotide and Pasireotide (Octreotide 100µgs . c .
thrice daily, followed by Pasireotide 200, 400 or 600µgs . c .
twice daily for 28 days each) for the eﬀect on GH, tumour
growth, and glucose metabolism. The GH concentration was
reduced to below 2.5µg/L in 9% and 19% of the patients for
Octreotide and Pasireotide, respectively. In patients treated
with Pasireotide for 3 months the response rate increased to
27%.Overallareductionofthetumourvolumeofmorethan
20% was observed in 39% of the patients during treatment
with Octreotide followed by Pasireotide. Side eﬀects were
comparable to those of Octreotide. However, the negative
eﬀect on glucose metabolism was more pronounced with
Pasireotide [141].
Somatoprim. A recently developed somatostatin multi-
receptor ligand, Somatoprim, may be at least as potent,
as Octreotide, but without a negative eﬀect on glucose
metabolism. This molecule has a GH suppressing eﬀect but
a very low insulin-suppressing action in vitro [63, 142, 143].
If these in vitro data are conﬁrmed in vivo in acromegalic
patients, Somatoprim will be a valuable alternative to other
SRL.
Chimeric Molecules. Another approach has been the devel-
opment of “chimeric” molecules. These molecules bind
to two diﬀerent types of receptors, to the somatostatin-
(subtypes2and5)andthedopamineD2receptor[144–146].International Journal of Endocrinology 9
A substantial number of somatotroph adenomas express
both sst and D2 receptors. Dopamine agonists inhibit GH
secretion in some acromegalic patients and an additive
suppressive eﬀect on GH secretion can be demonstrated in
some patients when dopamine agonists are added to SRL
treatment. However, when preliminary in vitro results were
followed by a “proof-of-principle” clinical trial the results
failed to show any additional eﬀect of this chimeric molecule
on GH secretion.
Conclusions. SRL are the ﬁrst-line treatment in patients with
insuﬃciently controlled GH secretion after surgery. The slow
release formulations Octreotide LAR and Lanreotide Autogel
are equally eﬀective. Up to 60% of the patients will achieve
complete remission and the rate increases with prolonged
treatment. Primary treatment with SRL should be reserved
for those rare patients who refuse or have contraindications
to surgery. Primary medical therapy may achieve tumour
stabilisation in most patients. Eﬃcacy of primary medi-
cal therapy may be comparable to postoperative medical
therapy. With long-term therapy a dose reduction may be
possible. Long-acting SRL are well tolerated. Preoperative
SRL therapy oﬀers no advantage in microadenomas, but
may be indicated in large macroadenomas to reduce tumour
volume and/or perioperative complications.
3.2. Dopamine Agonists (DAs). Dopamine agonists suppress
GHsecretiononlymodestlyinmostpatientsandhavelargely
been replaced by somatostatin receptor ligands. However,
they are much cheaper than SRL or Pegvisomant and can be
taken orally. At present they are mainly used as an adjunct to
insuﬃcient SRL therapy.
In healthy man dopamine agonists stimulate GH secre-
tion, while in acromegalic patients GH secretion is paradoxi-
callyinhibited.In1972Liuzzietal.detectedtheparadoxGH-
reducing eﬀect of L-Dopa in patients with acromegaly [147].
This resulted in the development of the “ﬁrst-generation”
dopamineagonistpreparation,Bromocriptine,andwassoon
followed by “second-generation” dopamine agonists such
as Cabergoline and Quinagolide (a nonergot dopamine
agonist). These have a longer half-life and fewer side eﬀects.
DAs bind preferentially with high aﬃnity to dopamine
2 (D2) receptors. Due to a high ﬁrst-pass eﬀect in the




of bromocriptine (nausea, vomiting, abdominal discomfort,
constipation, or diarrhoea) can be reduced by a very slow
dose increase. First-generation DA—Bromocriptine, Lisurid
and Methysergid—are now rarely used in acromegalic
patients. The second generation DAs have to be taken
daily (Quinagolide) or once to twice weekly (Cabergoline).
Increasing the dose to more than the recommended maximal
dose does not increase eﬃcacy, but results in worse side
eﬀe c t s .D A sh a v eb e e nr e p o r t e dt ob em o r ee ﬀective in
adenomas that co-secrete prolactin (PRL), which express
more D2 receptors [148], but this has not been universally
conﬁrmed [149]. It would, however, be compatible with
the good response to DA treatment in monohormonal
prolactinomas.
Cabergoline. Cabergoline is more eﬀective than Bromocrip-
tine, Methysergid, or Lisurid. The plasma half-life of Caber-
goline is between 62 and 115 hours. With weekly intake,
steady state is achieved after approximately 4 weeks. With a
dose of 1.75mg/week to 2.75mg/week the GH concentration
declinedtobelow2µg/Lin46%ofthepatientsandtheIGF-1
concentration was reduced to below 300µg/L in 39% [150].
The excellent results of this publication may be attributable
to a high number of patients with mamma-somatroph or
mixed lacto-somatroph adenomas. In a Belgian multicentre
trial with 64 acromegalic patients receiving Cabergoline 1–
1.75mg/d once weekly, the IGF-1 concentration declined
to below 300µg/L in 8 of 16 (50%) patients with GH/PRL
cosecretion and in 39% of the whole group. The GH
concentration declined to below 2µg/L in 46% of all patients
[148]. Similar responses (normal IGF-1 concentration 34%,
GH < 2.5µg/L 48%, resp.) are reported in a meta-analysis
of nine studies representing 149 patients [151]. In contrast
Freda and coworkers found a persistently normal IGF-
1 concentration in only 3 of 14 (21%) patients, without
a preferential eﬀect in patients with hyperprolactinemia
[149]. Overall the eﬀect of Cabergoline correlates with the
initial GH/IGF-1 concentration, that is, the lower the initial
GH/IGF-1 concentration the higher the probability of a
signiﬁcant decline or normalisation of the GH and IGF-1
concentration, respectively.
Tumour shrinkage occurred in 13 of 21 patients, with
a mass reduction by more than half in 5 GH-/PRL co-
secreting adenomas [148]. In ﬁve studies that prospectively
investigated tumour shrinkage during Cabergoline therapy
tumour shrinkage was associated with a higher baseline PRL
and IGF-1 concentration [151].
Quinagolide. Quinagolide is a nonergot selective D2 agonist.
Half-life during steady state is about 17 hours. There are
relatively few data on the eﬀectof Quinagolide in acromegaly
[152–156]. After a single 150µg dose of Quinagolide the
GH concentration decreased by 49% in ten acromegalic
patients [154]. Lombardi et al. treated 12 patients resistant
to SRL therapy with Quinagolide 150µg/d in a prospective,
placebo-controlled trial. In 33% of the patients the GH
concentration declined from 35µg/L to 2.7µg/L. Increasing
the dose to 300µg/d added one more responder. The
seven patients unresponsive to Quinagolide were subjected
to a combination therapy of Octreotide (600µg/d), and
Quinagolide (600µg/d) for three months. In two of these
combined therapy induced a greater GH reduction than
either medication alone [156]. Colao et al. compared the
eﬀect of Bromocriptine, Cabergoline, and Quinagolide in 34
acromegalicpatients. Theyconcludedthatboth,Cabergoline
and Bromocriptine (given as a LAR preparation), cannot
be considered useful medical approaches for acromegaly,
whereas Quinagolide normalised circulating GH and IGF-
I levels in 47.8% of patients [150]. However, normalisation10 International Journal of Endocrinology
wasdeﬁnedasaGHconcentrationbelow5µg/LandtheIGF-
1v a l u e sw e r en o ta g e - a d j u s t e d .
Conclusions. Monotherapy with a dopamine agonists should
be considered as ﬁrst-line treatment in patients with rela-
tively low GH and IGF-I concentrations in view of their low
cost and oral intake. They may be more eﬃcient in patients
whose adenoma co-secretes prolactin.
Combination Therapy of SRL and Dopamine Agonists. In
patients insuﬃciently responding to SRL or dopamine
agonist treatment, combination therapy may be an option
to further decrease GH secretion [151, 157–163]. Marzullo
et al.investigatedtheeﬀectofa6-monthtreatmentwithLan-
reotide (60–90mg/month), alone and in combination with
Cabergoline 1.5–3mg/week or Quinagolide (0.6mg/day)
in 10 acromegalic patients. The addition of dopamine
agonists resulted in a further decline of the GH and IGF-1
concentration not achieved by SRL treatment alone [158].
Minniti et al. studied the acute eﬀect of the combination
of Octreotide s.c. and Cabergoline in 21 patients with
acromegaly.In14patientswithinsuﬃcientresponsetoeither
drug, combination therapy was initiated (Octreotide 100µg
s.c. plus Cabergoline 0.5mg p.o. 24h before Octreotide)
resulting in a signiﬁcant further GH decline [157]. A more
recent investigation combing SRL slow release formula-
tions with Cabergoline (1–3.5mg/week) in 19 acromegalic
patients decreased GH to <2.5µg/L in four (21%) and
normalised the age-adjusted IGF-1 concentration in eight
patients (42%). The eﬀect was independent of the cosecre-
tion of PRL [159]. With IGF-1 concentration as an endpoint,
normalisation was observed in 19 patients (56%) with
alreadyrelativelylowIGF-IconcentrationonOctreotideLAR
monotherapy. The eﬀect was independent of the baseline
PRL concentration or GH/PRL co-expression [162, 163]. In
a meta-analysis Sandret et al. conﬁrmed the usefulness of
adding Cabergoline to SRL in patients with an insuﬃcient
eﬀect of SRL therapy. Cabergoline adjunction normalised
IGF-I in about 50% of cases. The change in the IGF-I
concentration was signiﬁcantly related to the baseline IGF-I
concentration but not to the dose of Cabergoline, the dura-
tion of treatment, or the baseline prolactin concentration
[151].
Side-Eﬀects. Side-eﬀects of dopamine agonist are given in
Table 2. They increase with the dose and can be prevented
by a slow increase of the dose. Nausea and orthostatic
dysregulation can be precluded by taking the dopamine
agonist at bedtime. Vasospastic adverse eﬀects require a
dose reduction. Side-eﬀects occur less often with the second
generation DA. However DA may induce a psychosis and this
can occur even after long-time exposure. Since a patient may
not notice the problem, relatives should be informed of this
possibleside-eﬀect.Preexistingpsychiatricillnessisarelative
contraindication to DA therapy. High dose Cabergoline
therapy has been reported to cause cardiac valvular abnor-
malities. With long-term, high dose Cabergoline therapy
echocardiographic follow-up has been recommended [61,
164, 165].
Conclusions. Dopamine agonist drugs may be used after
incomplete surgery in acromegalic patients. This is mainly
recommended in patients with only modestly elevated
GH/IGF-1 concentrations. Whether patients with PRL cose-
cretion will have a greater beneﬁt remains unclear. Cabergo-
line is most often used. DA monotherapy results in complete
remission in less than one third of the patients. Patients with
insuﬃcientGH/IGF-1suppressionduringSRLmonotherapy
may beneﬁt from addition of a dopamine agonist, which will
further lower GH/IGF-1 concentration in up to 50%. This
combination is substantially cheaper than the addition of a
GH-antagonist and should therefore be tried before adding
Pegvisomant (Figure 1).
3.3. Growth-Hormone Receptor-Antagonist. Following in-
complete surgery established medical therapies with SRL,
dopamine agonists or a combination of both successfully
reduce GH secretion in up to 75–80% of the patients. In
patients who fail to achieve complete remission growth-
hormone receptor-antagonist (GHA) therapy is an option.
Mechanism of Action. Pegvisomant, the only available GHA,
isananalogueofthe22kDGHmolecule.Modiﬁcationofthe
GH molecule, exchanging the amino acid glycin at position
120 in the third helix, results in a GH antagonistic eﬀect.
Further modiﬁcation, an exchange of eight amino acids at
the binding site-1, was thought to increase the aﬃnity to
the GH-receptor. However, it has been demonstrated that
this exchange does not aﬀect aﬃnity but removes two sites
for polyethylene glycol (PEG) binding, which are within the
native binding site [166, 167]. Thus modiﬁed, binding to the
receptor is reduced, requiring high plasma concentrations
of the GHA to competitively block the activation of the
receptor. Pegylation of the molecule prolongs the plasma
half-life from 15 minutes to 72 hours [168, 169]. Further-
more pegylation reduces immunogenicity of the molecule
as well as interaction with GH-binding proteins [167]. With
monotherapy the drug has to be injected subcutaneously on
a daily basis. Alternate day injections of Pegvisomant failed
to maintain IGF-1 within the age-adjusted range [170].
Peak serum Pegvisomant concentrations are attained
between 33–77 hours after administration. The half-life is
approximately 6 days, which is 6 times longer than the
daily 24-h dosing interval in clinical use. Thus peak-trough
ﬂuctuations at steady state during once daily dosing are
small [171]. Pegvisomant circulates at concentrations 100–
1000 times those of endogenous GH. An important question
was if Pegvisomant can cross the blood brain barrier via
putative choroid-plexus GH receptors and thus interacting
with GH-receptors at the hippocampus, cerebral cortex, and
hypothalamus, possibly inﬂuencing mood, cortical blood
ﬂow, and neuronal growth. Veldhuis et al. demonstrated,
based upon CSF measurements, that the pegylated GH-
receptor antagonist does not cross the human blood-brain
barrier [172].International Journal of Endocrinology 11
Table 2: Side-eﬀects.
Somatostatin analogues Dopamine agonists Pegvisomant
Often
Erythema at injection site Nausea/vomiting Headache
Swelling at injection site Headache Vertigo
Reduced appetite Vertigo Somnolence/asthenia
Nausea/vomiting Asthenia Tremor
Abdominal discomfort Diarrhoea/constipation Diarrhoea/constipation
Bloating Vasospasm Nausea/vomiting/bloating
Diarrhoea Oedema Sweating/pruritus
Gallstones Sleeping disorders Hypercholesterolemia




Abnormal liver function tests
Pain at injection site
Rare
Alopecia Orthostatic dysregulation Thrombocytopenia
Skin allergies Psychomotoric disturbances Leukocytopenia/leukocytosis
Bradycardia Visual hallucination Hyperaesthesia
Pancreatitis Psychosis Narcolepsy
Reversible acute hepatitis Retroperitoneal ﬁbrosis Visual disturbances
Vitamin B12 deﬁciency Valvular dysfunction m. Meniere







Table 3: Comparison of primary versus secondary medical therapy (mTx).
N Medication Dose
Remission (% of pats) Criteria for remission
Author
GH IGF-1 GH IGF-1
Prim. mTx 26 Octr. s.c. 777µg/d (mean) 43 68 <2µg/L Normal∗∗ Newman et
al. 1998 [135] Sec. mTx 81 635µg/d (mean) 22 62
P = ns P = ns
Prim. mTx 23 Lanr. SR 30mg/10–14d 64 51 basal GH
< 7.5U/L Normal∗ Baldelli et al.
2000 [136]
Sec. mTx 71 78 70
P<0.05 P<0.05
Prim. mTx 15 Octr. LAR 10–40mg/mo 73 53 <2.5µg/L or
<1µg/L (oGTT) Normal∗ Colao et al.
2001 [119]
Sec. mTx 21 76 71
P = ns P = ns
Prim. mTx 10 Octr. LAR or Lanr. SR 20mg/6w–
30mg/4w 50 60 <2µg/L Normal∗ Ayuk et al.
2002 [134]
Sec. + prim. mTx 22 30mg/2w–
30mg/10d 36 62
∗normal IGF-1 concentration, age adjusted; ∗∗normal IGF-1 concentration, not age adjusted.12 International Journal of Endocrinology
















Persistent acromegaly (according to the above criteria)
(Pegvisomant)
or

















symptoms of active acromegaly
reduced QoL (AcroQoL)
(Cabergoline)








Pegvisomant daily, titrating the
concentration





Start Pegvisomant once weekly,
Persistent acromegaly (according to the above criteria)
titrating the dose to normalise
Figure 1: Therapeutic algorithm.
Practical Issues. Due to the similarity between the structure
of GH and Pegvisomant most available GH assays cross-
react with Pegvisomant. Furthermore GH-receptor block-
ade induces a feedback increase of the endogenous GH
concentration. Therefore the determination of GH can no
longer be used as a parameter for therapeutic eﬃcacy. Hence
normalisation of the IGF-1 concentration is the therapeutic
goal. The determination of the IGF-1 concentration is used
forfollow-upduring therapy and dose adjustment.Problems
of the IGF-1 assay have already been discussed.
Further challenges for the evaluation of therapeutic
eﬃcacy refer to the concept of a dose-dependent tissue-
speciﬁc eﬀect of Pegvisomant. Adipose tissue, the kidneys,
and skeletal muscle seem to need less Pegvisomant to reduce
GH actions compared to the liver where more Pegvisomant
is required in order to reduce IGF-1 production [173].International Journal of Endocrinology 13
During Pegvisomant therapy normalisation of hepatic IGF-
1 synthesis may thus be accompanied by a status of
peripheral functional GH deﬁciency despite a normal IGF-
1 concentration. We found increased visceral obesity but
no improvement of glucose tolerance in 5 patients after 6
months of Pegvisomant therapy resulting in normal IGF-
1 concentrations. This combination supposedly indicates
peripheral GH deﬁciency with reduced lipolysis and a
subsequent increase in intra-abdominal fat mass, as well as
increased insulin resistance of the liver and muscle [174,
175]. These data reinforce the discussion about the concept
of “extra-hepatic acromegaly” [173] and the resulting need
for new biomarkers for the evaluation of therapeutic eﬃcacy
in acromegaly.
Therapeutic Eﬃcacy. Pegvisomant treatment results in nor-
malisation of the IGF-1 concentration in 90% to 97% of
patients with up to a maximal doses of 40mg/d s.c. or a
median dose of Pegvisomant of 130mg/week [176, 177].
The dose of Pegvisomant needed for normalisation of the
IGF-1 concentration is positively correlated to the basal age-
and sex-adjusted IGF-1 concentration and is independent
of pretreatment modalities (primary medical therapy ver-
sus postoperative therapy or combination therapy) [178].
Recently Ghigo et al. compared the eﬃcacy of Pegvisomant
and Octreotide LAR in an open randomized multicentre
study in 152 acromegalic patients. The normalisation rate
of IGF-1 was similar in both groups, but Pegvisomant was
more eﬀective in those patients with higher IGF-1 baseline
levels [179]. “Real world” data collected in the “Acrostudy,”
a large observational survey, demonstrated normalisation of
the IGF-1 concentration in only 60%–70% of the patients.
These results were possibly due to insuﬃcient dose titration
of Pegvisomant [180].
Combination Therapy of Pegvisomant and SRL. In consid-
eration of the high costs of Pegvisomant therapy Feenstra
et al. investigated the eﬀect of monthly Octreotide LAR
treatment in combination with Pegvisomant injected once
weekly with a dose of up to 80mg/week [178]. In patients
insuﬃciently treated with Octreotide LAR, normalisation
was achieved in 95%, on a median dose of 60mg (range 40–
80mg) Pegvisomant per week. In contrast, in another study
referred to by the authors, this dose, given as monotherapy,
resulted in normalisation of the IGF-1 concentration only in
about one third of the patients. Thus, combined treatment
allowed for a dose reduction of Pegvisomant compared
to the median 130mg/week dose used in the long-term
monotherapy trial [177].PossiblylessPegvisomantisneeded
when, due to the eﬀect of SRL, less growth hormone is to
compete with in the circulation. In addition, the reduction
of insulin in the portal vein during SRL therapy will decrease
the number of available GH-receptors and thus increase
the eﬃcacy of GH receptor blockade by Pegvisomant [178].
While combination therapy results in a signiﬁcant reduction
of the weekly Pegvisomant dose compared to monotherapy,
interindividual variability is high. This may be due the exon-
3polymorphismofthehumanGH-receptorgene.40%–50%
of the Western population carries an exon-3 deleted GH-
receptor. Pegvisomant therapy was more eﬀective in those
acromegalic patients positive for the exon-3 deletion of the
GH-receptor. A 20% lower dose per kg bodyweight achieved
normalisation of the IGF-1 concentration compared to
patients with the full-length receptor variant [181]. The
higher the dose of Pegvisomant in patients on monotherapy,
the higher is the probability of saving up to 50% of the dose
with concomitant SRL therapy. Thus combination therapy is
also more cost eﬃcient than monotherapy.
Clinical Eﬃcacy. In addition to assessing the biochemical
eﬀects of Pegvisomant therapy a small number of trials
focused on speciﬁc endpoints.
Cardiovascular Endpoints. Pivonello et al. reported a signiﬁ-
cant reduction of left ventricular hypertrophy and improved
diastolicandsystolicperformance[182].Anadditionalstudy
showedasigniﬁcantreductionofthediastolicbloodpressure
but no eﬀect on systolic blood pressure in four hypertensive
patientsonantihypertensivemedicationduringPegvisomant
therapy [183]. However, overall cardiovascular improvement
is probably less than with SRL, due to a possible additional
and direct eﬀect of SRL on cardiac tissue [184].
Pegvisomant therapy resulted in a reduction of the
tongue volume and this was accompanied by a decrease of
the apnoea-hypopnoea index in patients with sleep-apnoea.
In this small study the decline of both parameters did not
correlate with the decline of the IGF-1 concentration [185].
The brachial artery vascular function, which is known to
be decreased in active acromegaly, improved in 10 patients
treated with 10–40mg/d Pegvisomant for 18 months [186].
Metabolic Eﬀects. During short-term (4 weeks) administra-
tion of Pegvisomant the IGF-1 concentration (normalisation
of the IGF-1 concentration in four of the ﬁve patients),
and the insulin concentration declined. Insulin sensitivity
of basal lipolysis and endogenous glucose production were
enhanced compared to baseline [187]. The fasting glucose-
and insulin concentration, as well as the homeostasis model
assessment index (HOMA), an estimate of insulin resistance,
declined during Pegvisomant compared to baseline. While
total cholesterol concentration remained unchanged, HDL
cholesterol increased signiﬁcantly in patients on a daily
Pegvisomant dose ranging from 10 to 40mg/d during a
treatmentperiodof12months.SerumIGF-1hadnormalised
in 75% of the patients, but there was no correlation to the
observed metabolic changes [183].
Bone Formation. Patients with acromegaly tend to have
normal or even slightly increased bone mineral density.
However both, markers of bone formation and resorption,
have been found to be increased, as was the risk for vertebral
fractures. Jimenez et al. showed in a small heterogeneous
group of seven acromegalic patients, treated with 20mg
Pegvisomant for at least 18 months, a small but signiﬁcant
increase in bone mineral density [188, 189]. If conﬁrmed in
a larger cohort these results raise interesting questions on the14 International Journal of Endocrinology
interaction of increased GH concentrations or even of the
GH-receptor antagonist Pegvisomant with other receptors,
that is, the prolactin receptor or so far unknown receptors
that positively interact with bone formation.
Quality of Life. The IGF-1 concentration has been shown
to be a poor indicator of complete clinical remission.
Thus, to assess the clinical eﬃcacy of Pegvisomant therapy
Quality of Life (QoL) Questionnaires speciﬁcally developed
for acromegalic patients have been used to monitor clinical
eﬃcacy of the medication. In a prospective, double blind,
placebo-controlled, cross-over investigation QoL as well as
symptoms scores were assessed with or without Pegvisomant
in acromegalic patients with IGF-1 within normal limits.
With Pegvisomant 40mg/week QoL and symptoms scores
improved. However, there was no correlation between the
IGF-1 concentration and the improvement of QoL [190].
Side Eﬀects
Tumour Growth. Due to the mechanism of action some
safety considerations regarding possible tumour growth
during Pegvisomant therapy had to be considered. In a
large survey comprising 307 patients an increase in pituitary
volume was reported in 18 (5.9%) of the patients [191].
Tumour growth was conﬁrmed in 8 patients on reevaluation
of the MRI. In three of these patients preceding long-
term tumour growth could be demonstrated, irrespective
of the therapy applied. In two patients tumour growth was
most probably due to the reexpansion of the adenoma after
withdrawal of SRL therapy before initiating Pegvisomant.
In the remaining three patients minor tumour growth was
diagnosed 14 months after initiation of Pegvisomant. The
volume increase was considered clinically irrelevant and
Pegvisomant therapy was continued. In six of the eight
patients with tumour growth, the GH concentration could
be determined by a speciﬁc assay excluding cross-reaction
with Pegvisomant. All had an increase of the endogenous
GH concentration above 60ng/mL, while this was the case
in only 44 (13.6%) of patients without tumour growth. Thus
determination of the GH concentration during Pegvisomant
with an assay that does not crossreact with the drug might
identify those patients at risk for tumour growth. Overall,
the risk of Pegvisomant-induced tumour growth was felt to
be very low [191].
Other Side Eﬀects
Increase of Liver Enzymes. Overall the drug is well tol-
erated and subjective complaints are few. An increase in
liver enzymes has been observed and is reversible after
ending treatment with Pegvisomant [192]. Small increases
in transaminases (>3 times upper limit of normal, N =
20) normalised spontaneously in 10/20 patients despite
ongoing therapy [193]. Cholestatic liver dysfunction, with a
histologicaldiagnosisofdrug-relatedlivertoxicity,developed
in a patient with Gilbert syndrome and resolved after
treatment was stopped [194]. Subsequently the authors
surveyed 36 Spanish patients on Pegvisomant and found
the UGT1A1∗28 polymorphism associated with Gilbert
syndrome to be a signiﬁcant predictor of the risk of liver
function abnormalities during Pegvisomant therapy [195].
Basalliverfunctiontestsshouldbeperformedandmonitored
monthly during the titration phase and repeated at longer
intervals thereafter.
Lipohypertrophy. In the German Acrostudy 12 out of 371
patients reported some degree of lipohypertrophy [193]. An
impressive form of lipohypertrophy has been illustrated by
Buyuktas et al. in one patient [196]. Pathophysiologically
the GH antagonism of Pegvisomant may reduce the lipolytic
eﬀectof GH and thus increase local fat deposition. Untreated
acromegalic patients have a decreased fat mass due to the
lipolytic eﬀect of GH. Increased lipolysis causes insulin
resistance and deterioration of glucose tolerance. If GH is
normalised by surgery, the increased lipolysis will disappear
and fat mass, insulin sensitivity, and GT will subsequently
normalize. However, if GH is normalised by SRL therapy,
the drug induced suppression of insulin secretion, directly
andviasuppressionofGLP-1[92],increaseslipolysis.Hence,
the decreased fat mass and glucose intolerance persist, but
they are now drug-induced. In contrast, during Pegvisomant
therapy, GH no longer stimulates lipolysis due to the
blockade of its receptor, while insulin action is unabated.
Therefore, insulin sensitivity should improve and fat mass,
includingintra-abdominalfat,shouldincrease.Thishasbeen
conﬁrmed in ﬁve acromegalic patients on Pegvisomant. We
demonstrated a signiﬁcant increase of intra-abdominal fat
by electron beam computer tomography, while the amount
of subcutaneous abdominal fat remained unchanged [174].
Sinceintra-abdominalfatisacardiovascularriskfactorlong-
term follow-up is necessary to show whether detrimental
complications will develop.
Conclusions. The GH-receptor antagonist Pegvisomant nor-
malises IGF-1 concentration in up to 97% of the patients.
The dose is titrated to normalize IGF-1 concentration,
because GH cannot be routinely measured and serve as
an indicator for therapeutic eﬃcacy, due to cross-reactivity
of the routinely used GH assay with Pegvisomant. Because
of problems with the available IGF-1 assays the evaluation
of therapy progress and eﬃcacy may be diﬃcult. It has
been demonstrated that combined therapy with SRL is
almost as eﬀective as Pegvisomant monotherapy, but can be
substantially more cost-eﬀective. The drug is well tolerated
and the risk for tumour regrowth during therapy seems to
be low. The eﬀect on adipose tissue and its consequences will
have to be kept in mind. Liver function tests should be used
to monitor therapy. However in most cases liver toxicity is
reversible. Antibody development against Pegvisomant has
been observed, their clinical relevance is unknown.
4. Overall Conclusions
Medical therapy of acromegaly is indicated in patients who
failed to achieve the current remission criteria, that is, (i) aInternational Journal of Endocrinology 15
GH nadir below 1µg/L during a 75g oral glucose load, (ii)
a normal age- and sex-adjusted IGF-1 concentration either
after surgery or following radiotherapy. In order to support
therapeutic decisions a mean GH concentration >2.5µg/L
and clear signs and symptoms of active acromegaly argue
for further therapy. Therapeutic interventions should be
orientated on those biochemical indices that indicate a safe
GH/IGF-1 concentration, as data on complete remission or
even cure of acromegaly are still highly controversial due to
problems of assay technologies and standardisation.
Medical therapy is mostly initiated with SRL. However
because of the high price of all SRL, dopamine agonists
should be the initial therapeutic principle in patients with
low basal GH/IGF-1 concentrations. Up to 10% will achieve
remissionwithdopamine agonistmonotherapyalone.IfSRL
insuﬃciently suppresses GH secretion dopamine agonists
can be added, preferentially Cabergoline, and this will
normalise GH secretion in up to 50% of these patients. If
dopamine agonists fail to normalise GH secretion, combi-
nation therapy of SRL and Pegvisomant is recommended.
Combination therapy rather than Pegvisomant monother-
apy is preferred due to its higher cost-eﬀectiveness. With
these therapeutic strategies up to 95% of the patients will
achieve complete remission (Figure 1).
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